Current and emerging treatments for amyotrophic lateral sclerosis
Open Access
- 1 November 2009
- journal article
- review article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 5, 577-595
Abstract
Current and emerging treatments for amyotrophic lateral sclerosis Stefano Zoccolella1, Andrea Santamato2, Paolo Lamberti31Azienda Ospedaliero-UniversitariaOspedali Riuniti, Department of Medical and Neurological Sciences, Clinic of Nervous System Diseases, University of Foggia, Italy; 2Department of Physical Medicine and Rehabilitation, University of Foggia, OORR, Italy; 3Department of Neurology and Psychiatry, University of Bari, ItalyBackground: Amyotrophic lateral sclerosis (ALS) is a relatively rare neurodegenerative disorder of both upper and lower motoneurons. Currently, the management of ALS is essentially symptoms-based, and riluzole, an antiglutamatergic agent, is the only drug for the treatment of ALS approved by the food and drug administration.Objective: We reviewed current literature concerning emerging treatments for amyotrophic lateral sclerosis.Methods: A Medline literature search was performed to identify all studies on ALS treatment published from January 1st, 1986 through August 31st, 2009. We selected papers concerning only disease-modifying therapy.Results: Forty-eight compounds were identified and reviewed in this study.Conclusions: Riluzole is the only compound that demonstrated a beneficial effect on ALS patients, but with only modest increase in survival. Although several drugs showed effective results in the animal models for ALS, none of them significantly prolonged survival or improved quality of life of ALS patients. Several factors have been implicated in explaining the predominantly negative results of numerous randomized clinical trials in ALS, including methodological problems in the use of animal-drug screening, the lack of assessment of pharmacokinetic profile of the drugs, and methodological pitfalls of clinical trials in ALS patients.Keywords: amyotrophic lateral sclerosis, therapy, drug, survivalKeywords
This publication has 159 references indexed in Scilit:
- Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern ItalyEuropean Journal of Neurology, 2007
- The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJournal of Neurochemistry, 2007
- Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2006
- β-Lactam antibiotics are multipotent agents to combat neurological diseasesBiochemical and Biophysical Research Communications, 2005
- Celastrol Blocks Neuronal Cell Death and Extends Life in Transgenic Mouse Model of Amyotrophic Lateral SclerosisNeurodegenerative Diseases, 2005
- High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyJournal of Neural Transmission, 2004
- Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsAmyotrophic Lateral Sclerosis, 2004
- Xaliproden in amyotrophic lateral sclerosis: early clinical trialsAmyotrophic Lateral Sclerosis, 2004
- A therapeutic role for cyclooxygenase‐2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosisThe FASEB Journal, 2003
- Increased Survival and Function of SOD1 Mice After Glial Cell-Derived Neurotrophic Factor Gene TherapyHuman Gene Therapy, 2002